Tango Therapeutics (TNGX) Free Cash Flow (2020 - 2026)

Tango Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$44.4 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 6.23% year-over-year to -$44.4 million in Q1 2026; TTM through Mar 2026 was -$141.8 million, a 4.12% decrease from a year earlier, with the FY2025 full-year figure at -$139.2 million, down 5.24% from the prior year.
• Free Cash Flow fell to -$44.4 million in Q1 2026 per TNGX's latest filing, from -$29.8 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$24.2 million in Q2 2024 and bottomed at -$44.4 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$31.0 million (2022), against an average of -$32.4 million.
• Across the five-year window, Free Cash Flow plunged 322.75% in 2022 and grew 20.41% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$29.3 million in 2022, then grew by 10.58% to -$26.2 million in 2023, then plunged by 42.85% to -$37.4 million in 2024, then increased by 20.41% to -$29.8 million in 2025, then sank by 48.85% to -$44.4 million in 2026.
• Per Business Quant, the three latest TNGX Free Cash Flow figures stand at -$44.4 million (Q1 2026), -$29.8 million (Q4 2025), and -$30.9 million (Q3 2025).